Last reviewed · How we verify
Tralokinumab + TCS
Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis.
Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | Tralokinumab + TCS |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | IL-13 inhibitor |
| Target | IL-13 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
IL-13 is a cytokine involved in the pathogenesis of atopic dermatitis. By inhibiting IL-13, tralokinumab reduces inflammation and improves symptoms. When combined with TCS, it enhances the anti-inflammatory effect.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (PHASE3)
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (PHASE3)
- Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (PHASE3)
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (PHASE3)
- Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |